» Articles » PMID: 37176788

Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 May 13
PMID 37176788
Authors
Affiliations
Soon will be listed here.
Abstract

Treat-to-target is a therapeutic approach based on adjustments to treatment at set intervals in order to achieve well-defined, clinically relevant targets. This approach has been successfully applied to many chronic conditions, and in rheumatology promising results have emerged for rheumatoid arthritis. For systemic lupus erythematosus (SLE), defining the most meaningful treatment targets has been challenging, due to disease complexity and heterogeneity. Control of disease activity, the reduction of damage accrual and the patient's quality of life should be considered as the main targets in SLE, and several new drugs are emerging to achieve these targets. This review is focused on describing the target to achieve in SLE and the methods to do so, and it is also aimed at discussing if treat-to-target could be a promising approach also for this complex disease.

Citing Articles

Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.

Nikolopoulos D, Lourenco M, Depascale R, Triantafyllias K, Parodis I Mediterr J Rheumatol. 2024; 35(Suppl 2):328-341.

PMID: 39193182 PMC: 11345603. DOI: 10.31138/mjr.290424.eci.


Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus.

Suszek D, Dubaj M, Bigosinski K, Dembowska A, Kaniewski M, Sielwanowska W Reumatologia. 2024; 62(3):187-195.

PMID: 39055730 PMC: 11267658. DOI: 10.5114/reum.2024.141291.

References
1.
Kernder A, Elefante E, Chehab G, Tani C, Mosca M, Schneider M . The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?. Rheumatology (Oxford). 2020; 59(Suppl5):v63-v68. PMC: 7719037. DOI: 10.1093/rheumatology/keaa427. View

2.
Rovin B, Teng Y, Ginzler E, Arriens C, Caster D, Romero-Diaz J . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10289):2070-2080. DOI: 10.1016/S0140-6736(21)00578-X. View

3.
Durcan L, ODwyer T, Petri M . Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019; 393(10188):2332-2343. DOI: 10.1016/S0140-6736(19)30237-5. View

4.
Morand E, Furie R, Tanaka Y, Bruce I, Askanase A, Richez C . Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2019; 382(3):211-221. DOI: 10.1056/NEJMoa1912196. View

5.
Zonana-Nacach A, Barr S, Magder L, Petri M . Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000; 43(8):1801-8. DOI: 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O. View